121 related articles for article (PubMed ID: 9816174)
1. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.
Lindnér P; Heath D; Howell S; Naredi P; Hafström L
Clin Cancer Res; 1996 Feb; 2(2):311-7. PubMed ID: 9816174
[TBL] [Abstract][Full Text] [Related]
2. Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide.
Lindnér P; Heath DD; Shalinsky DR; Howell SB; Naredi P; Hafström L
Surg Oncol; 1993; 2(2):105-12. PubMed ID: 8252198
[TBL] [Abstract][Full Text] [Related]
3. Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique.
Oman M; Tölli J; Naredi P; Hafström LO
Cancer Chemother Pharmacol; 2004 Sep; 54(3):213-8. PubMed ID: 15138707
[TBL] [Abstract][Full Text] [Related]
4. Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model.
Pestieau SR; Stuart OA; Sugarbaker PH
Eur J Surg Oncol; 2000 Nov; 26(7):696-700. PubMed ID: 11078617
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic study of intraperitoneal etoposide.
O'Dwyer PJ; LaCreta FP; Daugherty JP; Hogan M; Rosenblum NG; O'Dwyer JL; Comis RL
Cancer Res; 1991 Apr; 51(8):2041-6. PubMed ID: 2009523
[TBL] [Abstract][Full Text] [Related]
6. A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.
Los G; Smals OA; van Vugt MJ; van der Vlist M; den Engelse L; McVie JG; Pinedo HM
Cancer Res; 1992 Mar; 52(5):1252-8. PubMed ID: 1737387
[TBL] [Abstract][Full Text] [Related]
7. [Preoperative intraperitoneal versus intravenous carboplatin chemotherapy for advanced gastric cancer, pharmacokinetics and drug accumulation study].
Wang J; Chen J; Ma S
Zhonghua Zhong Liu Za Zhi; 1997 Jul; 19(4):300-2. PubMed ID: 11038765
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model.
Glehen O; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):79-84. PubMed ID: 15048586
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological bases of intraperitoneal chemotherapy].
Gladieff L; Chatelut E; Dalenc F; Ferron G
Bull Cancer; 2009 Dec; 96(12):1235-42. PubMed ID: 19923051
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Marchettini P; Stuart OA; Mohamed F; Yoo D; Sugarbaker PH
Cancer Chemother Pharmacol; 2002 Jun; 49(6):499-503. PubMed ID: 12107555
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y; Fujiwara K; Kigawa J; Itamochi H; Nagao S; Aotani E; Terakawa N; Kohno I;
Gynecol Oncol; 2005 Dec; 99(3):591-6. PubMed ID: 16095677
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.
McClay EF; Goel R; Andrews P; Gorelick S; Kirmani S; Kim S; Braly P; Plaxe S; Hoff S; Alcaraz J
Br J Cancer; 1993 Oct; 68(4):783-8. PubMed ID: 8398708
[TBL] [Abstract][Full Text] [Related]
15. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics.
de Lima Vazquez V; Stuart OA; Mohamed F; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Aug; 52(2):108-12. PubMed ID: 12759776
[TBL] [Abstract][Full Text] [Related]
16. Treatment of peritoneal carcinomatosis using carboplatin-loaded hydroxyapatite particles.
Takeyama H; Mohri N; Mizuno I; Akamo Y; Sawai H; Manabe T; Yotsuyanagi T; Nakamura S
Anticancer Res; 2006; 26(6B):4603-6. PubMed ID: 17201184
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
18. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
19. [Intraperitoneal and intrathoracic administration of hydroxyapatite-carboplatin (HAp-CBDCA)].
Mohri N; Mizuno I; Akamo Y; Takeyama H; Manabe T
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1791-3. PubMed ID: 10560396
[TBL] [Abstract][Full Text] [Related]
20. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
Hande K; Messenger M; Wagner J; Krozely M; Kaul S
Clin Cancer Res; 1999 Oct; 5(10):2742-7. PubMed ID: 10537337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
